FIGURE 8.
Comparison of the expression of immune checkpoint genes and sensitivity to clinical treatment between high- and low-risk groups. (A) Expression of immune checkpoint genes among the two groups. (B) TIDE score of the two groups. (C) The signature can be used as a potential predictor of sorafenib sensitivity, as low-risk scores are associated with a lower IC50 for sorafenib.